Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Other Rheumatic Conditions

Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA

Reuters Staff  |  January 16, 2016

NEW YORK (Reuters Health)—Almost half of juvenile idiopathic arthritis (JIA) patients treated with etanercept achieve minimal disease activity after one year of treatment, according to new findings. Younger patients and those who did not require corticosteroid treatment were more likely to have an excellent response, Dr. Kimme Hyrich of the University of Manchester in the…

Study Uncovers Tet2’s Role in Resolving Inflammation

Lara C. Pullen, PhD  |  January 11, 2016

When investigating the role of epigenetic modifiers in inflammatory response, researchers found that Tet2 acts at the chromatin level to help resolve inflammation in both dendritic cells and macrophage, repressing the transcription of IL-6…

How to Manage Polymyalgia Rheumatica

Mary Beth Nierengarten  |  December 16, 2015

Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2 Specifically, the recommendations offer guidance on the use of…

GPA Patient Carries NORD Banner to Top of Mt. Everest

Carol Patton  |  December 16, 2015

On May 23, 2010, Cindy Abbott was standing on top of the world. She had spent the past 51 days climbing Mount Everest, the tallest mountain in the world, and had finally reached the summit. “I was very anxious to get off and get back down,” she says, adding that the summit is about the…

Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s

Will Boggs, MD  |  December 13, 2015

NEW YORK (Reuters Health)—Careful use of antibiotics and corticosteroids can substantially improve the safety of autologous hematopoietic stem transplantation (HSCT) in patients with refractory Crohn’s disease (CD), researchers from Spain report. “Autologous HSCT is feasible but it is associated with severe adverse events and even mortality,” Dr. Elena Ricart from Hospital Clinic de Barcelona tells…

Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Will Boggs, MD  |  December 8, 2015

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) commonly develop skin lesions related to anti-tumor necrosis factor (anti-TNF) medications, according to a retrospective study. “We were most surprised by the relatively high percentage (30%) of patients developing skin problems while being treated with anti-TNF agents,” Dr. Isabelle Cleynen from KU Leuven, Belgium, tells Reuters…

Mycophenolate Sodium Effective for Chronic Noninfectious Pediatric Uveitis

Reuters Staff  |  December 1, 2015

NEW YORK (Reuters Health)—Mycophenolate sodium (MPS) is effective for treating children with chronic noninfectious uveitis, researchers from Germany report. “Mycophenolate sodium could be used as a preferred steroid-sparing agent in children with chronic noninfectious intermediate uveitis,” Dr. Deshka Doycheva, from the University of Tuebingen, Germany, told Reuters Health by email. MPS is an enteric-coated formulation…

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

Robert I. Fox, MD, PhD, & Carla M. Fox, RN  |  November 17, 2015

Despite a generation of advances in molecular biology, a huge gap exists between the Sjögren’s syndrome (SS) patient’s description of their symptoms and the objective findings. Current issues include: Many SS patients are misclassified as either rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), even within rheumatology clinics. Frequently, the sickest SS patients with extraglandular…

Fellows’ Forum Case Report: Palmar Fasciitis & Polyarthritis Syndrome

Naveen Raj, DO, MPH, Marc Kesselman, DO, & Barry Waters, MD  |  November 16, 2015

Case report: A 78-year-old Caucasian female presented to our outpatient rheumatology clinic with pain in her bilateral shoulders, hands and knees that began suddenly one month earlier. She admitted to stiffness in her hands lasting several hours, and expressed an inability to extend her fingers. She denied fever, rashes, jaw claudication, headache or visual changes….

Research in Temporal Arteritis Suggests Link with Infection, Autoimmune Disease

Shamik Bhattacharyya, MD, MS  |  November 16, 2015

Temporal arteritis was first described by Sir Jonathan Hutchinson in 1890 in an elderly retired gentleman’s servant who developed red, painful streaks on his temples and was found to have bilaterally swollen temporal arteries with feeble pulses.1 Sir Hutchinson disputed the suggestion that the red streaks were caused by the man’s hat and, instead, called…

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 35
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences